Table 3 Baseline characteristics of the study population
From: Immune monitoring after pediatric liver transplantation – the prospective ChilSFree cohort study
Subjects | n (%) / median (range) |
|---|---|
Sex | |
Male | 142 (56%) |
Female | 112 (44%) |
Age | 2.5 years (0.2–18.0) |
Diagnosis | |
Biliary atresia | 101 (39.8%) |
Malignant liver disease | 24 (9.4%) |
Metabolic liver disease | 21 (8.3%) |
Acute liver failure | 10 (3.9%) |
PSC | 7 (2.8%) |
PFIC | 12 (4.7%) |
Alagille syndrome | 11 (4.3%) |
Cystic fibrosis | 11 (4.3%) |
Wilson’s disease | 4 (1.6%) |
Congenital hepatic fibrosis | 3 (1.2%) |
Toxic liver damage | 1 (0.4%) |
Other | 49 (19.3%) |
Type of graft | |
Living related transplantation | 73 (28.7%) |
Cadaveric transplantation | 181 (71.3%) |
ABO compatibility | |
ABO compatible | 241 (94.9%) |
ABO incompatible | 13 (5.1%) |